MODIFIED ANTI-HEPARIN/PF4 COMPLEX ANTIBODY AND HIT ANTIBODY STANDARD

Provided is a modified antibody which enables the quantitative measurement of the amount of a heparin/PF4 complex, an onset factor of heparin-induced trombocytopenia (HIT), without the influence of the presence of PF4, and which can be used as an HIT antibody standard specific for the heparin/PF4 co...

Full description

Saved in:
Bibliographic Details
Main Author HOSHINO NOBUHIRO
Format Patent
LanguageEnglish
Published 14.07.2011
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
ENZYMOLOGY
FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES
MEASURING
METALLURGY
MICROBIOLOGY
MUTATION OR GENETIC ENGINEERING
ORGANIC CHEMISTRY
PEPTIDES
PHYSICS
SPIRITS
TESTING
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:Provided is a modified antibody which enables the quantitative measurement of the amount of a heparin/PF4 complex, an onset factor of heparin-induced trombocytopenia (HIT), without the influence of the presence of PF4, and which can be used as an HIT antibody standard specific for the heparin/PF4 complex. The modified antibody is prepared by linking a human IgG, or an antibody fragment derived from a human IgG, to a monoclonal antibody obtained by immunizing an animal (excluding a human) with the heparin/PF4 complex.
Bibliography:Application Number: US200913061072